iOrganBio, an innovator in intelligent cell manufacturing, announced today the appointment of Lee L. Rubin, Ph.D., to its Scientific Advisory Board. Dr. Rubin is a recognized authority in stem cell biology, regenerative medicine, and translational neuroscience, whose research has significantly advanced the understanding of neurodegenerative diseases and contributed to the development of multiple therapeutic candidates. He serves as Co-Director and Principal Faculty of the Harvard Stem Cell Institute and Professor in Harvard’s Department of Stem Cell and Regenerative Biology.
Dr. Rubin’s pioneering work includes blood-brain barrier biology, neural stem cell differentiation, disease modeling using patient-derived induced pluripotent stem cells, and the discovery of therapeutic candidates for disorders such as Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). His expertise will be instrumental in expanding iOrganBio’s platform into neurological applications, leveraging the company’s CellForge™ platform, which combines AI prediction, biological sensing, and automated 3D incubation to engineer human cells and organoids with greater precision and consistency.
The appointment underscores iOrganBio’s commitment to advancing scalable production of human cells for disease modeling, drug discovery, and cell therapy development. Dr. Rubin’s academic and entrepreneurial leadership is expected to guide the company in developing FDA-aligned New Approach Methodologies (NAMs) that could reduce reliance on animal testing and accelerate therapeutic development. For more details, view the full announcement here.
iOrganBio’s CellForge platform uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. At its core is the functional human CellAtlas™, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This smart, closed-loop process delivers the accuracy, efficiency, and quality needed to turn scientific ideas into breakthroughs, accelerating disease modeling, regenerative medicine, and drug development. More information is available at iOrgan.Bio.
The addition of Dr. Rubin comes as iOrganBio continues to build its scientific advisory board with leading experts in cell biology and translational medicine. His experience in bringing discoveries from bench to bedside aligns with the company’s mission to redefine how human cells are engineered and produced at scale for research and therapeutic applications. With this appointment, iOrganBio strengthens its position at the forefront of intelligent cell manufacturing for neurological diseases.
